KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Short term Debt (2016 - 2025)

Historic Short term Debt for Sarepta Therapeutics (SRPT) over the last 11 years, with Q3 2025 value amounting to $36.0 million.

  • Sarepta Therapeutics' Short term Debt fell 6069.65% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 6069.65%. This contributed to the annual value of $105.5 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Short term Debt is $36.0 million, which was down 6069.65% from $91.6 million recorded in Q3 2024.
  • In the past 5 years, Sarepta Therapeutics' Short term Debt registered a high of $105.6 million during Q1 2024, and its lowest value of $36.0 million during Q3 2025.
  • Its 3-year average for Short term Debt is $86.0 million, with a median of $91.6 million in 2024.
  • Examining YoY changes over the last 5 years, Sarepta Therapeutics' Short term Debt showed a top increase of 6069.65% in 2025 and a maximum decrease of 6069.65% in 2025.
  • Quarter analysis of 3 years shows Sarepta Therapeutics' Short term Debt stood at $105.5 million in 2023, then fell by 13.17% to $91.6 million in 2024, then tumbled by 60.7% to $36.0 million in 2025.
  • Its Short term Debt stands at $36.0 million for Q3 2025, versus $91.6 million for Q3 2024 and $91.5 million for Q2 2024.